Small Molecule Healthcare Contract Manufacturing Market Size, Share & Trends Analysis Report By Type (API, Finished Drug Product), By Therapeutic Area, By Region, And Segment Forecasts, 2025 - 2033
Description
Small Molecule Healthcare Contract Manufacturing Market Summary
The global small molecule healthcare contract manufacturing market size was estimated at USD 109.04 billion in 2024 and is projected to reach USD 310.6 billion by 2033, growing at a CAGR of 12.56% from 2025 to 2033. The market growth is driven by the increasing demand for cost-efficient drug production, the expanding pipeline of small molecule therapeutics, and the rising trend of outsourcing among pharmaceutical companies to focus on core competencies such as R&D and commercialization.
In addition, the market is driven by the rising outsourcing of manufacturing activities by pharmaceutical companies seeking to reduce operational costs, enhance flexibility, and accelerate time-to-market. Developing and commercializing new small-molecule drugs requires significant capital investment and specialized infrastructure, prompting companies to rely on contract manufacturing organizations (CMOs) for production efficiency. The increasing demand for generic and branded small molecule drugs, coupled with the expanding pipeline of therapeutics targeting chronic diseases such as cancer, cardiovascular disorders, and diabetes, is further boosting the need for scalable, high-quality manufacturing services.
Furthermore, technological advancements in process chemistry, analytical methods, and continuous manufacturing are further enhancing production efficiency and yield in small molecule manufacturing. The growing focus on high-potency active pharmaceutical ingredients (HPAPIs) and complex formulations has also encouraged pharmaceutical companies to partner with specialized CDMOs that possess advanced containment and regulatory capabilities.
Global Small Molecule Healthcare Contract Manufacturing Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global small molecule healthcare contract manufacturing market report based on phase, service, therapeutic area, end use, and region:
The global small molecule healthcare contract manufacturing market size was estimated at USD 109.04 billion in 2024 and is projected to reach USD 310.6 billion by 2033, growing at a CAGR of 12.56% from 2025 to 2033. The market growth is driven by the increasing demand for cost-efficient drug production, the expanding pipeline of small molecule therapeutics, and the rising trend of outsourcing among pharmaceutical companies to focus on core competencies such as R&D and commercialization.
In addition, the market is driven by the rising outsourcing of manufacturing activities by pharmaceutical companies seeking to reduce operational costs, enhance flexibility, and accelerate time-to-market. Developing and commercializing new small-molecule drugs requires significant capital investment and specialized infrastructure, prompting companies to rely on contract manufacturing organizations (CMOs) for production efficiency. The increasing demand for generic and branded small molecule drugs, coupled with the expanding pipeline of therapeutics targeting chronic diseases such as cancer, cardiovascular disorders, and diabetes, is further boosting the need for scalable, high-quality manufacturing services.
Furthermore, technological advancements in process chemistry, analytical methods, and continuous manufacturing are further enhancing production efficiency and yield in small molecule manufacturing. The growing focus on high-potency active pharmaceutical ingredients (HPAPIs) and complex formulations has also encouraged pharmaceutical companies to partner with specialized CDMOs that possess advanced containment and regulatory capabilities.
Global Small Molecule Healthcare Contract Manufacturing Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global small molecule healthcare contract manufacturing market report based on phase, service, therapeutic area, end use, and region:
- Service Outlook (Revenue, USD Million, 2021 - 2033)
- API
- Development & Scale-up Services
- Finished dose formulations
- Packaging
- Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
- Oncology
- Cardiovascular Disease
- Neurological Disorders
- Infectious Diseases
- Orthopedic Diseases
- Metabolic Disorders
- Autoimmune Diseases
- Gastrointestinal Disorders
- Respiratory Diseases
- Ophthalmology
- Dental Diseases
- Others
- End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Pharmaceutical Companies
- Biotechnology Companies
- Others
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Norway
- Sweden
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East and Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
- Oman
- Qatar
Table of Contents
150 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR’s internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Value chain based analysis (Model 2)
- 1.7.3. Multivariate Analysis (Model 3)
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Landscape Insights
- Chapter 3. Small Molecule Healthcare Contract Manufacturing Market: Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Ancillary Market Outlook
- 3.2. Small Molecule Healthcare Contract Manufacturing Market Dynamics
- 3.2.1. Market Driver Impact Analysis
- 3.2.2. Market Restraint Analysis
- 3.2.3. Market Opportunities
- 3.3. Technological Landscape
- 3.4. Pricing Model Analysis
- 3.5. Tariff Impact Analysis
- 3.6. Supply Chain Analysis
- 3.7. Market Analysis Tools
- 3.7.1. Porter’s Five Forces Analysis
- 3.7.2. PESTEL by SWOT Analysis
- Chapter 4. Small Molecule Healthcare Contract Manufacturing Market: Service Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Global Small Molecule Healthcare Contract Manufacturing Market Service Movement Analysis
- 4.3. Global Small Molecule Healthcare Contract Manufacturing Market Size & Trend Analysis, by Service, 2021 to 2033 (USD Million)
- 4.4. Active Pharmaceutical Ingredient (API)
- 4.4.1. Active Pharmaceutical Ingredient (API) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.5. Development & Scale-up Services
- 4.5.1. Development & Scale-up Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6. Finished dose formulations
- 4.6.1. Finished dose formulations Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.7. Packaging
- 4.7.1. Packaging Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 5. Small Molecule Healthcare Contract Manufacturing Market: Therapeutic Area Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Global Small Molecule Healthcare Contract Manufacturing Market Therapeutic Area Movement Analysis
- 5.3. Global Small Molecule Healthcare Contract Manufacturing Market Size & Trend Analysis, by Therapeutic Area, 2021 to 2033 (USD Million)
- 5.4. Oncology
- 5.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.5. Cardiovascular Disease
- 5.5.1. Cardiovascular Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.6. Neurological Disorders
- 5.6.1. Neurological Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.7. Infectious Diseases
- 5.7.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.8. Orthopedic Diseases
- 5.8.1. Orthopedic Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.9. Metabolic Disorders
- 5.9.1. Metabolic Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.10. Autoimmune Diseases
- 5.10.1. Autoimmune Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.11. Gastrointestinal Disorders
- 5.11.1. Gastrointestinal Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.12. Respiratory Diseases
- 5.12.1. Respiratory Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.13. Ophthalmology
- 5.13.1. Ophthalmology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.14. Dental Diseases
- 5.14.1. Dental Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.15. Others
- 5.15.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 6. Small Molecule Healthcare Contract Manufacturing Market: End Use Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Global Small Molecule Healthcare Contract Manufacturing Market End Use Movement Analysis
- 6.3. Global Small Molecule Healthcare Contract Manufacturing Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
- 6.4. Pharmaceutical Companies
- 6.4.1. Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5. Biotechnology Companies
- 6.5.1. Biotechnology Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6. Others
- 6.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 7. Small Molecule Healthcare Contract Manufacturing Market: Regional Estimates & Trend Analysis by Service, Service, End Use
- 7.1. Regional Market Dashboard
- 7.2. Global Regional Market Snapshot
- 7.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
- 7.4. North America
- 7.4.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.2. U.S.
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Competitive Scenario
- 7.4.2.3. Regulatory Framework
- 7.4.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.3. Canada
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Competitive Scenario
- 7.4.3.3. Regulatory Framework
- 7.4.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.4. Mexico
- 7.4.4.1. Key Country Dynamics
- 7.4.4.2. Competitive Scenario
- 7.4.4.3. Regulatory Framework
- 7.4.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5. Europe
- 7.5.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.2. UK
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Competitive Scenario
- 7.5.2.3. Regulatory Framework
- 7.5.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.3. Germany
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Competitive Scenario
- 7.5.3.3. Regulatory Framework
- 7.5.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.4. France
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Competitive Scenario
- 7.5.4.3. Regulatory Framework
- 7.5.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.5. Italy
- 7.5.5.1. Key Country Dynamics
- 7.5.5.2. Competitive Scenario
- 7.5.5.3. Regulatory Framework
- 7.5.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.6. Spain
- 7.5.6.1. Key Country Dynamics
- 7.5.6.2. Competitive Scenario
- 7.5.6.3. Regulatory Framework
- 7.5.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.7. Denmark
- 7.5.7.1. Key Country Dynamics
- 7.5.7.2. Competitive Scenario
- 7.5.7.3. Regulatory Framework
- 7.5.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.8. Sweden
- 7.5.8.1. Key Country Dynamics
- 7.5.8.2. Competitive Scenario
- 7.5.8.3. Regulatory Framework
- 7.5.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.9. Norway
- 7.5.9.1. Key Country Dynamics
- 7.5.9.2. Competitive Scenario
- 7.5.9.3. Regulatory Framework
- 7.5.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6. Asia Pacific
- 7.6.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.2. Japan
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Competitive Scenario
- 7.6.2.3. Regulatory Framework
- 7.6.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.3. China
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Competitive Scenario
- 7.6.3.3. Regulatory Framework
- 7.6.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.4. India
- 7.6.4.1. Key Country Dynamics
- 7.6.4.2. Competitive Scenario
- 7.6.4.3. Regulatory Framework
- 7.6.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.5. Australia
- 7.6.5.1. Key Country Dynamics
- 7.6.5.2. Competitive Scenario
- 7.6.5.3. Regulatory Framework
- 7.6.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.6. South Korea
- 7.6.6.1. Key Country Dynamics
- 7.6.6.2. Competitive Scenario
- 7.6.6.3. Regulatory Framework
- 7.6.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.7. Thailand
- 7.6.7.1. Key Country Dynamics
- 7.6.7.2. Competitive Scenario
- 7.6.7.3. Regulatory Framework
- 7.6.7.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7. Latin America
- 7.7.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.2. Brazil
- 7.7.2.1. Key Country Dynamics
- 7.7.2.2. Competitive Scenario
- 7.7.2.3. Regulatory Framework
- 7.7.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.3. Argentina
- 7.7.3.1. Key Country Dynamics
- 7.7.3.2. Competitive Scenario
- 7.7.3.3. Regulatory Framework
- 7.7.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8. Middle East & Africa
- 7.8.1. Middle East & Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.2. South Africa
- 7.8.2.1. Key Country Dynamics
- 7.8.2.2. Competitive Scenario
- 7.8.2.3. Regulatory Framework
- 7.8.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.3. Saudi Arabia
- 7.8.3.1. Key Country Dynamics
- 7.8.3.2. Competitive Scenario
- 7.8.3.3. Regulatory Framework
- 7.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.4. UAE
- 7.8.4.1. Key Country Dynamics
- 7.8.4.2. Competitive Scenario
- 7.8.4.3. Regulatory Framework
- 7.8.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.5. Kuwait
- 7.8.5.1. Key Country Dynamics
- 7.8.5.2. Competitive Scenario
- 7.8.5.3. Regulatory Framework
- 7.8.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.6. Oman
- 7.8.6.1. Key Country Dynamics
- 7.8.6.2. Competitive Scenario
- 7.8.6.3. Regulatory Framework
- 7.8.6.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.7. Qatar
- 7.8.7.1. Key Country Dynamics
- 7.8.7.2. Competitive Scenario
- 7.8.7.3. Regulatory Framework
- 7.8.7.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 8. Competitive Landscape
- 8.1. Company Categorization
- 8.1.1. Market Leaders
- 8.1.2. Emerging Players
- 8.2. Small Molecule Healthcare Contract Manufacturing Market Position Analysis, 2024
- 8.3. Company Profiles
- 8.3.1. Lonza Group
- 8.3.1.1. Company Overview
- 8.3.1.2. Financial Performance
- 8.3.1.3. Service Benchmarking
- 8.3.1.4. Strategic Initiatives
- 8.3.2. Catalent Inc.
- 8.3.2.1. Company Overview
- 8.3.2.2. Financial Performance
- 8.3.2.3. Service Benchmarking
- 8.3.2.4. Strategic Initiatives
- 8.3.3. Recipharm AB
- 8.3.3.1. Company Overview
- 8.3.3.2. Financial Performance
- 8.3.3.3. Service Benchmarking
- 8.3.3.4. Strategic Initiatives
- 8.3.4. Thermo Fisher Scientific Inc.
- 8.3.4.1. Company Overview
- 8.3.4.2. Financial Performance
- 8.3.4.3. Service Benchmarking
- 8.3.4.4. Strategic Initiatives
- 8.3.5. WuXi AppTec
- 8.3.5.1. Company Overview
- 8.3.5.2. Financial Performance
- 8.3.5.3. Service Benchmarking
- 8.3.5.4. Strategic Initiatives
- 8.3.6. Cambrex Corporation
- 8.3.6.1. Company Overview
- 8.3.6.2. Financial Performance
- 8.3.6.3. Service Benchmarking
- 8.3.6.4. Strategic Initiatives
- 8.3.7. Eurofins Scientific
- 8.3.7.1. Company Overview
- 8.3.7.2. Financial Performance
- 8.3.7.3. Service Benchmarking
- 8.3.7.4. Strategic Initiatives
- 8.3.8. Siegfried Holding AG
- 8.3.8.1. Company Overview
- 8.3.8.2. Financial Performance
- 8.3.8.3. Service Benchmarking
- 8.3.8.4. Strategic Initiatives
- 8.3.9. CordenPharma
- 8.3.9.1. Company Overview
- 8.3.9.2. Financial Performance
- 8.3.9.3. Service Benchmarking
- 8.3.9.4. Strategic Initiatives
- 8.3.10. PCI Pharma Services
- 8.3.10.1. Company Overview
- 8.3.10.2. Financial Performance
- 8.3.10.3. Service Benchmarking
- 8.3.10.4. Strategic Initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
